Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has been given a $12.00 price target by stock analysts at Maxim Group in a report released on Wednesday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s price target indicates a potential upside of 120.99% from the stock’s previous close.

Other equities analysts also recently issued reports about the company. HC Wainwright set a $13.00 price target on Inovio Pharmaceuticals and gave the stock a “buy” rating in a research note on Saturday, June 3rd. Piper Jaffray Companies upgraded Inovio Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $14.00 price target for the company in a research note on Thursday, June 8th. Jefferies Group LLC reiterated a “neutral” rating and issued a $38.00 price target on shares of Inovio Pharmaceuticals in a research note on Monday, May 1st. BNP Paribas reiterated a “neutral” rating and issued a $39.00 price target on shares of Inovio Pharmaceuticals in a research note on Monday, May 1st. Finally, Zacks Investment Research upgraded Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 price target for the company in a research note on Tuesday, July 11th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the stock. Inovio Pharmaceuticals presently has an average rating of “Buy” and an average price target of $20.78.

Shares of Inovio Pharmaceuticals (NASDAQ:INO) opened at 5.43 on Wednesday. The company has a 50 day moving average price of $7.16 and a 200-day moving average price of $6.84. The firm’s market capitalization is $405.22 million. Inovio Pharmaceuticals has a 12 month low of $5.32 and a 12 month high of $9.95.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.31) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.31). The business had revenue of $10.40 million during the quarter, compared to the consensus estimate of $5.83 million. Inovio Pharmaceuticals had a negative return on equity of 65.97% and a negative net margin of 235.91%. The company’s revenue for the quarter was up 28.4% compared to the same quarter last year. During the same period last year, the firm earned ($0.11) earnings per share. Equities research analysts expect that Inovio Pharmaceuticals will post ($1.06) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Maxim Group Analysts Give Inovio Pharmaceuticals, Inc. (INO) a $12.00 Price Target” was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. and international copyright law. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/08/09/maxim-group-analysts-give-inovio-pharmaceuticals-inc-ino-a-12-00-price-target.html.

In other Inovio Pharmaceuticals news, Director David B. Weiner sold 8,000 shares of Inovio Pharmaceuticals stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $8.00, for a total value of $64,000.00. Following the completion of the transaction, the director now directly owns 740,956 shares in the company, valued at $5,927,648. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 10.60% of the company’s stock.

Several institutional investors have recently modified their holdings of INO. Bank of America Corp DE increased its position in shares of Inovio Pharmaceuticals by 14.6% in the first quarter. Bank of America Corp DE now owns 28,256 shares of the biopharmaceutical company’s stock valued at $188,000 after buying an additional 3,605 shares in the last quarter. American International Group Inc. increased its position in shares of Inovio Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 40,856 shares of the biopharmaceutical company’s stock valued at $270,000 after buying an additional 2,695 shares in the last quarter. Private Capital Advisors Inc. acquired a new position in shares of Inovio Pharmaceuticals during the second quarter valued at about $274,000. Metropolitan Life Insurance Co. NY increased its position in shares of Inovio Pharmaceuticals by 8.5% in the first quarter. Metropolitan Life Insurance Co. NY now owns 51,573 shares of the biopharmaceutical company’s stock valued at $341,000 after buying an additional 4,020 shares in the last quarter. Finally, State of Wisconsin Investment Board acquired a new position in shares of Inovio Pharmaceuticals during the second quarter valued at about $392,000. Institutional investors and hedge funds own 22.92% of the company’s stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.